Published in J Virol on June 01, 1995
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75
CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med (1997) 5.18
Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol (1997) 3.93
Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J Virol (1997) 3.33
Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J Virol (1998) 3.11
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol (2006) 2.97
Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. J Exp Med (1997) 2.31
A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol (1999) 2.12
Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol (2011) 1.95
Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol (2004) 1.92
Retroviral superinfection resistance. Retrovirology (2005) 1.82
Reawakening retrocyclins: ancestral human defensins active against HIV-1. PLoS Biol (2009) 1.80
Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol (1998) 1.69
The kappaB sites in the human immunodeficiency virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for viral growth. J Virol (1997) 1.59
Inhibition of simian immunodeficiency virus (SIV) replication by CD8(+) T lymphocytes from macaques immunized with live attenuated SIV. J Virol (1998) 1.59
Inhibition of HIV-1 endocytosis allows lipid mixing at the plasma membrane, but not complete fusion. Retrovirology (2011) 1.49
Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol (2004) 1.43
Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques. J Virol (2010) 1.41
HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation. Virology (2007) 1.40
Proteomic studies reveal coordinated changes in T-cell expression patterns upon infection with human immunodeficiency virus type 1. J Virol (2008) 1.40
Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1. J Virol (2001) 1.29
Role of the extracellular domain of human herpesvirus 7 glycoprotein B in virus binding to cell surface heparan sulfate proteoglycans. J Virol (1997) 1.27
Membrane-anchored peptide inhibits human immunodeficiency virus entry. J Virol (2001) 1.20
Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles. BMC Infect Dis (2002) 1.20
Characterization of entry mechanisms of human herpesvirus 8 by using an Rta-dependent reporter cell line. J Virol (2003) 1.20
The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques. PLoS One (2010) 1.19
Level of ICAM-1 surface expression on virus producer cells influences both the amount of virion-bound host ICAM-1 and human immunodeficiency virus type 1 infectivity. J Virol (1998) 1.18
Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob Agents Chemother (2009) 1.15
Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue. J Virol (2007) 1.14
Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture. J Clin Microbiol (2006) 1.10
Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides. J Virol (2005) 1.06
Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc Natl Acad Sci U S A (1997) 1.03
A new monoclonal antibody, mAb 4A12, identifies a role for the glycosaminoglycan (GAG) binding domain of RANTES in the antiviral effect against HIV-1 and intracellular Ca2+ signaling. J Exp Med (1998) 1.01
Wild-type-like viral replication potential of human immunodeficiency virus type 1 envelope mutants lacking palmitoylation signals. J Virol (2005) 1.01
Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism. J Virol (1999) 1.00
Mutations in the leucine zipper-like heptad repeat sequence of human immunodeficiency virus type 1 gp41 dominantly interfere with wild-type virus infectivity. J Virol (1998) 1.00
Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers. Antimicrob Agents Chemother (2010) 0.99
Human immunodeficiency virus bearing a disrupted central DNA flap is pathogenic in vivo. J Virol (2007) 0.98
The T cell receptor triggering apparatus is composed of monovalent or monomeric proteins. J Biol Chem (2011) 0.97
Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition. J Virol (2001) 0.97
Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity. J Virol (2005) 0.96
Productive entry of HIV-1 during cell-to-cell transmission via dynamin-dependent endocytosis. J Virol (2013) 0.96
Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides. Gene Ther (2008) 0.95
Use of tissue culture cell lines to evaluate HIV antiviral resistance. AIDS Res Hum Retroviruses (2008) 0.93
Enhancement of human immunodeficiency virus type 1 envelope-mediated fusion by a CD4-gp120 complex-specific monoclonal antibody. J Virol (1997) 0.93
Inhibition of human immunodeficiency virus type 1 infection of human CD4+ T cells by microbial HSP70 and the peptide epitope 407-426. J Virol (2007) 0.92
Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution. Retrovirology (2008) 0.92
Human immunodeficiency virus type 1 membrane fusion mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer. J Virol (1996) 0.92
Construction of a doxycycline-dependent simian immunodeficiency virus reveals a nontranscriptional function of tat in viral replication. J Virol (2007) 0.92
Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor. Proc Natl Acad Sci U S A (2012) 0.91
Hepatitis C virus infection of human T lymphocytes is mediated by CD5. J Virol (2012) 0.91
mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5. Nucleic Acids Res (2015) 0.91
Induction of galectin-1 expression by HTLV-I Tax and its impact on HTLV-I infectivity. Retrovirology (2008) 0.89
Lens epithelium-derived growth factor/p75 qualifies as a target for HIV gene therapy in the NSG mouse model. Mol Ther (2012) 0.88
Saquinavir inhibits early events associated with establishment of HIV-1 infection: potential role for protease inhibitors in prevention. Antimicrob Agents Chemother (2012) 0.88
Intercellular adhesion molecule 1 promotes HIV-1 attachment but not fusion to target cells. PLoS One (2012) 0.88
The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations. Virology (2010) 0.87
Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide. Antimicrob Agents Chemother (2012) 0.86
Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity. FASEB J (2011) 0.86
Conformational epitope consisting of the V3 and V4 loops as a target for potent and broad neutralization of simian immunodeficiency viruses. J Virol (2013) 0.86
Stimulated plasmacytoid dendritic cells impair human T-cell development. Blood (2006) 0.85
DC-SIGN increases the affinity of HIV-1 envelope glycoprotein interaction with CD4. PLoS One (2011) 0.85
Hemofiltrate CC chemokine 1[9-74] causes effective internalization of CCR5 and is a potent inhibitor of R5-tropic human immunodeficiency virus type 1 strains in primary T cells and macrophages. Antimicrob Agents Chemother (2002) 0.85
Cell-type specific requirements for thiol/disulfide exchange during HIV-1 entry and infection. Retrovirology (2012) 0.84
Secreted antiviral entry inhibitory (SAVE) peptides for gene therapy of HIV infection. Mol Ther (2011) 0.83
Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load. Antimicrob Agents Chemother (2012) 0.83
Differential expression of candidate virus receptors in human T lymphocytes prone or resistant to infection with patient-derived hepatitis C virus. PLoS One (2013) 0.83
Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity. Antimicrob Agents Chemother (2015) 0.82
Inhibition of HIV-1 infection by human α-defensin-5, a natural antimicrobial peptide expressed in the genital and intestinal mucosae. PLoS One (2012) 0.82
trans-dominant interference with human immunodeficiency virus type 1 replication and transmission in CD4(+) cells by an envelope double mutant. J Virol (1999) 0.82
Isolation and molecular characterization of a nelfinavir (NFV)-resistant human immunodeficiency virus type 1 that exhibits NFV-dependent enhancement of replication. J Virol (2003) 0.82
Grifonin-1: a small HIV-1 entry inhibitor derived from the algal lectin, Griffithsin. PLoS One (2010) 0.82
Increased infectivity in human cells and resistance to antibody-mediated neutralization by truncation of the SIV gp41 cytoplasmic tail. Front Microbiol (2013) 0.82
Toll-like receptor 3 signalling up-regulates expression of the HIV co-receptor G-protein coupled receptor 15 on human CD4+ T cells. PLoS One (2014) 0.81
The superior folding of a RANTES analogue expressed in lactobacilli as compared to mammalian cells reveals a promising system to screen new RANTES mutants. Protein Expr Purif (2009) 0.81
Broad-spectrum inhibition of HIV-1 by a monoclonal antibody directed against a gp120-induced epitope of CD4. PLoS One (2011) 0.81
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PLoS One (2013) 0.81
Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays. J Clin Microbiol (2010) 0.80
Sequences in the U3 region of human immunodeficiency virus 1 improve efficiency of minus strand transfer in infected cells. Virology (2010) 0.80
Chemokines and HIV: The First Close Encounter. Front Immunol (2015) 0.80
Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains. J Transl Med (2015) 0.79
The impact of HIV-1 genetic diversity on the efficacy of a combinatorial RNAi-based gene therapy. Gene Ther (2015) 0.79
Continued utilization of CCR5 coreceptor by a newly derived T-cell line-adapted isolate of human immunodeficiency virus type 1. J Virol (1998) 0.79
Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection. J Virol (2011) 0.78
Upstream AUG codons in the simian immunodeficiency virus SIVmac239 genome regulate Rev and Env protein translation. J Virol (2012) 0.78
Sialic acid-binding Ig-like lectin-7 interacts with HIV-1 gp120 and facilitates infection of CD4pos T cells and macrophages. Retrovirology (2013) 0.78
The impact of unprotected T cells in RNAi-based gene therapy for HIV-AIDS. Mol Ther (2013) 0.78
Mutations in matrix and SP1 repair the packaging specificity of a Human Immunodeficiency Virus Type 1 mutant by reducing the association of Gag with spliced viral RNA. Retrovirology (2010) 0.78
Rice endosperm is cost-effective for the production of recombinant griffithsin with potent activity against HIV. Plant Biotechnol J (2016) 0.77
Combination of the CCL5-derived peptide R4.0 with different HIV-1 blockers reveals wide target compatibility and synergic cobinding to CCR5. Antimicrob Agents Chemother (2014) 0.76
The role of mononuclear phagocytes in HTLV-III/LAV infection. Science (1986) 17.33
Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science (1993) 13.87
Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science (1987) 12.77
HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA. Cell (1986) 12.74
Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell (1986) 10.70
Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science (1991) 10.53
Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science (1990) 10.13
HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature (1990) 9.72
Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell (1989) 9.66
Biologic features of HIV-1 that correlate with virulence in the host. Science (1988) 9.06
Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients. Cell (1986) 9.01
Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature (1991) 8.80
Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci U S A (1988) 8.40
A molecular clone of HTLV-III with biological activity. Nature (1985) 8.30
Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol (1992) 7.92
Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science (1986) 7.81
Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A (1988) 7.74
Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet (1986) 7.09
Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci U S A (1988) 6.74
High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A (1990) 6.49
HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. J Acquir Immune Defic Syndr (1989) 6.16
Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol (1988) 5.96
Genomic diversity of human T-lymphotropic virus type III (HTLV-III). Science (1985) 5.33
Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proc Natl Acad Sci U S A (1991) 5.26
Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1. J Virol (1990) 5.20
Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes. Proc Natl Acad Sci U S A (1985) 5.10
Extensive variation of human immunodeficiency virus type-1 in vivo. Nature (1988) 5.02
Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol (1988) 4.96
Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41. Proc Natl Acad Sci U S A (1990) 4.64
Biologically diverse molecular variants within a single HIV-1 isolate. Nature (1988) 3.80
Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol (1994) 3.70
Envelope glycoprotein of HIV induces interference and cytolysis resistance in CD4+ cells: mechanism for persistence in AIDS. Cell (1988) 3.12
Changes in the transmembrane region of the human immunodeficiency virus type 1 gp41 envelope glycoprotein affect membrane fusion. J Virol (1990) 2.95
Specific tropism of HIV-1 for microglial cells in primary human brain cultures. Science (1990) 2.74
Human immunodeficiency virus type 1 cellular host range, replication, and cytopathicity are linked to the envelope region of the viral genome. J Virol (1990) 2.72
The viral envelope gene is involved in macrophage tropism of a human immunodeficiency virus type 1 strain isolated from brain tissue. J Virol (1990) 2.04
Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. Science (1992) 1.76
Amino acid substitutions in the human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope. J Virol (1994) 1.55
Human immunodeficiency virus type 1 tropism for brain microglial cells is determined by a region of the env glycoprotein that also controls macrophage tropism. J Virol (1992) 1.52
Rapidly and slowly replicating human immunodeficiency virus type 1 isolates can be distinguished according to target-cell tropism in T-cell and monocyte cell lines. Proc Natl Acad Sci U S A (1989) 1.51
Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker. J Biol Chem (1993) 1.24
Human immunodeficiency virus (HIV) type 1 can superinfect HIV-2-infected cells: pseudotype virions produced with expanded cellular host range. Proc Natl Acad Sci U S A (1992) 1.11
Interference patterns of human immunodeficiency viruses HIV-1 and HIV-2. Virology (1990) 1.07
Multiple determinants for growth of human immunodeficiency virus type 1 in monocyte-macrophages. Virology (1995) 0.96
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32
Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science (1984) 32.33
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1980) 30.08
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science (1995) 17.42
The role of mononuclear phagocytes in HTLV-III/LAV infection. Science (1986) 17.33
HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA. Cell (1986) 12.74
Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature (1977) 12.57
Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science (1984) 11.30
Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A (1982) 11.15
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71
Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell (1986) 10.70
Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science (1984) 10.40
Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci U S A (1978) 9.59
The trans-activator gene of HTLV-III is essential for virus replication. Nature (1986) 8.65
Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci U S A (1988) 8.40
A molecular clone of HTLV-III with biological activity. Nature (1985) 8.30
Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science (1986) 8.15
Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization. Proc Natl Acad Sci U S A (1986) 8.06
Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res Hum Retroviruses (1987) 7.85
Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science (1986) 7.81
Onc gene amplification in promyelocytic leukaemia cell line HL-60 and primary leukaemic cells of the same patient. Nature (1982) 6.78
Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science (1986) 6.53
Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat. Science (1985) 6.51
Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science (1985) 6.48
Inhibition of development of Kaposi's sarcoma-related lesions by a bacterial cell wall complex. Science (1992) 6.35
Functional and morphologic characterization of human T cells continuously grown in vitro. J Immunol (1977) 6.30
Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions. J Virol (1987) 6.20
The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science (1987) 6.16
Long-term cultures of HTLV-III--infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science (1986) 5.86
Expression of cellular homologues of retroviral onc genes in human hematopoietic cells. Proc Natl Acad Sci U S A (1982) 5.80
The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med (1996) 5.46
Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS. Science (1984) 5.43
Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science (1985) 5.42
Genomic diversity of human T-lymphotropic virus type III (HTLV-III). Science (1985) 5.33
A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science (1982) 5.30
Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. Nature (1982) 5.11
Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes. Proc Natl Acad Sci U S A (1985) 5.10
HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature (1985) 5.10
Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet (1986) 5.05
Human T-lymphotropic retroviruses. Nature (1985) 5.04
Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned media. Proc Natl Acad Sci U S A (1980) 4.91
Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci U S A (1984) 4.90
Nucleotide sequence of cloned cDNA of human c-myc oncogene. Nature (1983) 4.83
Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science (1983) 4.72
Cloning and characterization of different human sequences related to the onc gene (v-myc) of avian myelocytomatosis virus (MC29). Proc Natl Acad Sci U S A (1982) 4.70
Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci U S A (1986) 4.68
Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line. Virology (1981) 4.68
Isolation and transmission of human retrovirus (human t-cell leukemia virus). Science (1983) 4.67
Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature (1990) 4.47
Seroepidemiology of HTLV-III antibody in Danish homosexual men: prevalence, transmission, and disease outcome. Br Med J (Clin Res Ed) (1984) 4.39
Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia. Nature (1981) 4.38
Differential expression of the amv gene in human hematopoietic cells. Proc Natl Acad Sci U S A (1982) 4.37
Molecular cloning and characterization of the HTLV-III virus associated with AIDS. Nature (1984) 4.35
Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses. Nature (1987) 4.35
Sequence homology and morphologic similarity of HTLV-III and visna virus, a pathogenic lentivirus. Science (1985) 4.31
Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses. Science (1990) 4.28
Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications. JAMA (1985) 4.26
Characterization and distribution of nucleic acid sequences of a novel type C retrovirus isolated from neoplastic human T lymphocytes. Proc Natl Acad Sci U S A (1981) 4.24
Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects. Science (1986) 4.17
Restricted expression of human T-cell leukemia--lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. Virology (1983) 4.11
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol (2002) 4.11
Biochemical and immunological analysis of human immunodeficiency virus gag gene products p17 and p24. J Virol (1988) 4.06
Viral DNA carried by human immunodeficiency virus type 1 virions. J Virol (1992) 3.93
Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. Science (1983) 3.82
Biologically diverse molecular variants within a single HIV-1 isolate. Nature (1988) 3.80
Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome. Lancet (1984) 3.77
Chromosomal sublocalization of human c-myb and c-fes cellular onc genes. Nature (1983) 3.77
Natural antibodies to the structural core protein (p24) of the human T-cell leukemia (lymphoma) retrovirus found in sera of leukemia patients in Japan. Proc Natl Acad Sci U S A (1982) 3.75
Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments. JAMA (1986) 3.74
Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol (1993) 3.68
Adult T-cell lymphoma-leukaemia in Blacks from the West Indies. Lancet (1982) 3.67
Human T lymphotropic virus type III infection of human alveolar macrophages. Blood (1986) 3.66
HTLV-III in saliva of people with AIDS-related complex and healthy homosexual men at risk for AIDS. Science (1984) 3.50
HTLV-III in cells cultured from semen of two patients with AIDS. Science (1984) 3.47
Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci U S A (1993) 3.45
Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat Med (1997) 3.44
A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med (1984) 3.41
Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J Virol (1990) 3.35
Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J Exp Med (1981) 3.30
The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. N Engl J Med (1996) 3.30
DNA-dependent DNA polymerases I and II from normal human-blood lymphocytes. Proc Natl Acad Sci U S A (1972) 3.27
Antigens encoded by the 3'-terminal region of human T-cell leukemia virus: evidence for a functional gene. Science (1984) 3.20
Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature (1986) 3.19
Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature (1994) 3.05
Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an AIDS endemic region. JAMA (1986) 3.05
Immunological and chemical analysis of P6, the carboxyl-terminal fragment of HIV P15. AIDS Res Hum Retroviruses (1987) 3.03
Transformation of human umbilical cord blood T cells by human T-cell leukemia/lymphoma virus. Proc Natl Acad Sci U S A (1983) 3.01
RNA dependent DNA polymerase of human acute leukaemic cells. Nature (1970) 2.96
Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS. N Engl J Med (1985) 2.95
AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science (1989) 2.93
Structure and expression of tat-, rev-, and nef-specific transcripts of human immunodeficiency virus type 1 in infected lymphocytes and macrophages. J Virol (1990) 2.93